# 2026-16998: FDA keeps metabolism experts on payroll till 2028

2026-16998, Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-20, effective 2026-08-27 (as of 2026-08-27).

- Canonical: https://policyrisk.com/federal-register/2026-16998
- As of: 2026-08-27
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16998
- Title: Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53876
- Published: 2026-08-20
- Effective: 2026-08-27
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-27

## In one line

FDA keeps metabolism experts on payroll till 2028

## Summary

The FDA is renewing its Endocrinologic and Metabolic Drugs Advisory Committee for two more years, keeping it active until August 27, 2028. This committee helps make sure drugs for hormone and metabolism issues are safe and effective. Doctors, scientists, and patients can count on this team to keep an eye on important medicines without any new costs or delays.

## Abstract

The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16998 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/20/2026-16998/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal)
- [2026-16998 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16998.pdf)

## Related
- [Previous: 2026-16997, Information Collection Being Reviewed by the Federal Communications Commission…](https://policyrisk.com/federal-register/2026-16997)
- [Next: 2026-16999, Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal](https://policyrisk.com/federal-register/2026-16999)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16998 (as of 2026-08-27).
